Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain; Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
Clin Nutr. 2018 Apr;37(2):580-589. doi: 10.1016/j.clnu.2017.01.010. Epub 2017 Jan 28.
BACKGROUND & AIMS: Visceral adipose tissue (VAT) has been shown to be profoundly responsible of most of the obesity-associated metabolic derangements. The measurement of VAT usually implies the use of imaging techniques such as magnetic resonance imaging or computed tomography (CT). Our aim was to evaluate the accuracy of the determination of VAT by means of abdominal bioimpedance (BIA) with the ViScan device in comparison with CT and its clinical usefulness in the management of obesity.
We studied a sample of 140 subjects (73 males/67 females) with BMI ranging from 17.7 to 50.4 kg/m to evaluate the accuracy of the ViScan in comparison to CT to determine VAT. To further analyze ViScan's clinical usefulness we studied a separate cohort (n = 2849) analyzing cardiometabolic risk factors. Furthermore, we studied the ability of the ViScan to detect changes in VAT after weight gain (n = 107) or weight loss (n = 335). The study was performed from October 2009 through June 2015.
ViScan determines VAT with a good accuracy in individuals with a CT-VAT up to 200 cm, and then with lower precision with increasing body mass, exhibiting a moderate-high correlation with CT-VAT (r = 0.75, P < 0.001). Importantly, VAT determination with the ViScan exhibits better correlations with several cardiometabolic risk factors such as glucose, triglycerides, HDL-cholesterol and markers of fatty liver than anthropometric measurements such as BMI or waist circumference. ViScan is able to detect VAT variations after body weight changes.
Since the possibility of measuring VAT by imaging techniques is not always available, abdominal BIA represents a good alternative to estimate VAT, allowing the identification of patients with increased VAT-related cardiometabolic risk and a better management of obese patients.
ClinicalTrials.gov NCT01055626 and NCT01572090.
内脏脂肪组织（VAT）被证明是导致大多数肥胖相关代谢紊乱的主要原因。VAT 的测量通常需要使用磁共振成像或计算机断层扫描（CT）等影像学技术。我们的目的是评估 ViScan 腹部生物阻抗（BIA）设备测量 VAT 的准确性，并与 CT 进行比较，及其在肥胖管理中的临床应用。
我们研究了 140 名 BMI 范围为 17.7 至 50.4 kg/m2 的受试者样本，以评估 ViScan 与 CT 相比确定 VAT 的准确性。为了进一步分析 ViScan 的临床应用价值，我们研究了另一组（n=2849）分析了心血管代谢危险因素。此外，我们还研究了 ViScan 检测体重增加（n=107）或体重减轻（n=335）后 VAT 变化的能力。该研究于 2009 年 10 月至 2015 年 6 月进行。
ViScan 在 CT-VAT 高达 200 cm 的个体中具有良好的准确性来确定 VAT，然后随着体重的增加精度降低，与 CT-VAT 呈中度高度相关（r=0.75，P<0.001）。重要的是，ViScan 确定的 VAT 与葡萄糖、甘油三酯、高密度脂蛋白胆固醇和脂肪肝标志物等多种心血管代谢危险因素的相关性优于 BMI 或腰围等人体测量指标。ViScan 能够检测体重变化后的 VAT 变化。
由于并非总是可以通过影像学技术测量 VAT，腹部 BIA 是估计 VAT 的一种很好的替代方法，可以识别具有增加的与 VAT 相关的心血管代谢风险的患者，并更好地管理肥胖患者。
ClinicalTrials.gov NCT01055626 和 NCT01572090。
